Azacitidine and Cisplatin in Patients With Advanced Lung or Head and Neck Cancer
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | February 2009 |
| End Date: | December 2011 |
Phase I Study of Azacitidine in Combination With Cisplatin in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck
The standard of care for head and neck and lung cancer includes chemotherapy, radiation and
surgery. For patients with cancer of head and neck or lung that recurs after surgery and/or
radiation, or has spread to other parts of body, chemotherapy using cisplatin can slow down
tumor growth and extend lifespan.
The study drug, azacitidine, can block the ability of some cancer cells to replicate, and
has been approved by the Food and Drug Administration for use in myelodysplastic syndrome,
which is a slowly developing blood cell-related cancer. In laboratory and animal experiments
using head and neck and lung cancer cells, azacitidine has been shown to be a cisplatin
"helper", (that is, it makes cisplatin more effective in stopping the growth of head and
neck and lung cancer. )
Since the combination of azacitidine and cisplatin has not been used in patients with head
and neck or lung cancer, the investigators are performing this study combining azacitidine
and cisplatin to find out what effects, good and/or bad, the study drug may have on patients
with advanced head and neck or lung cancer. The investigators are doing this study because
they would like to find a better treatment for these types of cancer.
Azacitidine will be given with standard dose of cisplatin. At the beginning of the study,
three patients will be treated with low dose of azacitidine. If that dose does not cause
bad side effects, then the dose will slowly be made higher for new patients who take part in
the study.
Patients will receive azacitidine as a once-a-day subcutaneous (under the skin) injection
every day from day 1 to day 5 of 28 days in this study. Cisplatin is given intravenously on
day 8. This 28-day or 4-week period of time is called a cycle. Cycles are repeated every
four weeks for as long as the physician recommends.
During this study, patients will need the following tests and procedures.
- Physical exam - This will be done weekly during first 2 weeks of every 4-week
treatment cycle.
- Blood tests for blood counts - These will be done every week.
- Blood tests for kidney function, liver function, and to measure electrolytes - These
will be done every week
- Blood samples for research study - This will be done weekly during first cycle, then
weekly during the first 2 weeks on the subsequent treatment cycles
- X-rays or scans - These will be done once every 8 weeks.
We found this trial at
1
site
Click here to add this to my saved trials
